e-learning
resources
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
Hubaux Roland, Vandermeers Fabian, Cosse Jean-Philippe, Crisanti Cecilia, Kapoor Veena, Albelda Steven M., Mascaux Céline, Delvenne Philippe, Hubert Pascale, Willems Luc
Source:
ERJ Open Res 2015; 1: 00028-2015
Journal Issue:
December
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hubaux Roland, Vandermeers Fabian, Cosse Jean-Philippe, Crisanti Cecilia, Kapoor Veena, Albelda Steven M., Mascaux Céline, Delvenne Philippe, Hubert Pascale, Willems Luc. Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models. ERJ Open Res 2015; 1: 00028-2015
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer
Source: Eur Respir J 2006; 27: 1183-1189
Year: 2006
VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study
Source: ERJ Open Res 2015; 1: 00029-2015
Year: 2015
Clinical experiences of amrubicin hydrochloride monotherapy in extensive-disease small cell lung cancer
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
Combination of erlotinib and bevacizumab in non small cell lung cancer patients
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Source: Eur Respir Rev 2015; 24: 582-593
Year: 2015
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Second-line treatment patients at relapse of disseminated small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 395s
Year: 2001
Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Pemetrexed continuation maintenance in patients with advanced lung adenocarcinoma
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
A study of paclitaxel in two dose combinations with carboplatin in the treatment of small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 319s
Year: 2001
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017
Year: 2018
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
Source: Eur Respir J 2011; 37: 129-135
Year: 2011
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
Source: Eur Respir J 2006; 27: 895-901
Year: 2006
Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 464s
Year: 2002
Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept